Loading market movers...

IMNN-001

Phase 2

Imunon, Inc. (IMNN)

00%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

IMNNPhase 2$8M

IMNN-001 Phase 2 Est. Readout (MRD)

IMNN-001• Epithelial Ovarian Cancer30

Q2 2027~QEstimated

00%

Competitive Landscape

2 competitors in Epithelial Ovarian Cancer

IMGNMirvetuximab Soravtansine

IMGNBevacizumab

View Full Landscape

Drug Information

Target Indication

Epithelial Ovarian Cancer

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IMNN

Imunon, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)Phase 3

Epithelial Ovarian Cancer

ThermoDoxPhase 3

Hepatocellular Carcinoma

DextrosePhase 3

Hepatocellular Carcinoma

IMNN-101Phase 2

SARS CoV 2 Infection

ThermoDox in combination with Microwave Hyperthermia (heat)Phase 2

Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts